CHEST:阿奇霉素治疗难治性咳嗽效果欠佳

2016-04-14 MedSci MedSci原创

慢性咳嗽是全球常见的临床问题。虽然许多患者有潜在症状,如哮喘,胃食管反流或鼻炎,但即使治疗了这些疾病还是会留下许多疾病症状。这样的患者群都需要新的治疗方法。来自美国的研究人员进行了一项随机,双盲,安慰剂对照试验,以确定每周250mg的阿齐霉素,一周三次,共8周,是否会影响44例治疗性咳嗽患者的莱斯特咳嗽问卷(LCQ)评分。视觉模拟评分法(VAS)和支气管呼出气一氧化氮被用来评估咳嗽严重程度,作为次

慢性咳嗽是全球常见的临床问题。虽然许多患者有潜在症状,如哮喘,胃食管反流或鼻炎,但即使治疗了这些疾病还是会留下许多疾病症状。这样的患者群都需要新的治疗方法。

来自美国的研究人员进行了一项随机,双盲,安慰剂对照试验,以确定每周250mg的阿齐霉素,一周三次,共8周,是否会影响44例治疗性咳嗽患者的莱斯特咳嗽问卷(LCQ)评分。视觉模拟评分法(VAS)和支气管呼出气一氧化氮被用来评估咳嗽严重程度,作为次要终点。

阿奇霉素组患者的LCQ得分有了重要的临床改善(平均改变,2.4; 95%CI,0.5至4.2),而安慰剂组患者却没有改善(平均改变,0.7; 95%CI,-0.6到1.9),但组间无统计学显著差异(P =0.12)。对于任何次要终点都没有显著组间差异。纵观有反应的亚组,在慢性咳嗽和诊断有哮喘病发症的患者中,阿奇霉素治疗后LCQ得分有了较大而显著的改善(平均值,6.19; 95%CI,4.06至8.32)。

低剂量阿齐霉素8周治疗与安慰剂相比,没有显著改善LCQ得分。本研究没有建议采用大环内酯类药物治疗顽固性咳嗽,但其或许可以治疗与哮喘有关的慢性咳嗽;这值得进一步探讨。

原始出处:

David Hodgson,John Anderson,Catherine Reynolds,et al.The Effects of Azithromycin in Treatment-Resistant Cough,CHEST,2016.4.14

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1816466, encodeId=c11018164661e, content=<a href='/topic/show?id=4e839e754f5' target=_blank style='color:#2F92EE;'>#阿奇霉素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97754, encryptionId=4e839e754f5, topicName=阿奇霉素治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLIQxicGuURvblbKDmmdLreAdrFKYA57y7viabog6mfk8dXQpQzYCf0ibcgoMnFrQ2MiaV8Iic4ocdhEfw/132, createdBy=0e3a2500177, createdName=ms1692810954239974, createdTime=Mon Jun 13 07:51:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929245, encodeId=6cf8192924567, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Mar 19 12:51:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84645, encodeId=c0d98464570, content=学习了啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Sun May 08 07:19:00 CST 2016, time=2016-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84646, encodeId=c32c84646cf, content=涨姿势了, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Sun May 08 07:19:00 CST 2016, time=2016-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050543, encodeId=71f5205054334, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jul 23 20:51:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528313, encodeId=f6f61528313dd, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sat Apr 16 05:51:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78462, encodeId=3530e8462f9, content=支原体吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Fri Apr 15 10:57:00 CST 2016, time=2016-04-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1816466, encodeId=c11018164661e, content=<a href='/topic/show?id=4e839e754f5' target=_blank style='color:#2F92EE;'>#阿奇霉素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97754, encryptionId=4e839e754f5, topicName=阿奇霉素治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLIQxicGuURvblbKDmmdLreAdrFKYA57y7viabog6mfk8dXQpQzYCf0ibcgoMnFrQ2MiaV8Iic4ocdhEfw/132, createdBy=0e3a2500177, createdName=ms1692810954239974, createdTime=Mon Jun 13 07:51:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929245, encodeId=6cf8192924567, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Mar 19 12:51:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84645, encodeId=c0d98464570, content=学习了啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Sun May 08 07:19:00 CST 2016, time=2016-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84646, encodeId=c32c84646cf, content=涨姿势了, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Sun May 08 07:19:00 CST 2016, time=2016-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050543, encodeId=71f5205054334, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jul 23 20:51:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528313, encodeId=f6f61528313dd, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sat Apr 16 05:51:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78462, encodeId=3530e8462f9, content=支原体吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Fri Apr 15 10:57:00 CST 2016, time=2016-04-15, status=1, ipAttribution=)]
    2017-03-19 Smile2680
  3. [GetPortalCommentsPageByObjectIdResponse(id=1816466, encodeId=c11018164661e, content=<a href='/topic/show?id=4e839e754f5' target=_blank style='color:#2F92EE;'>#阿奇霉素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97754, encryptionId=4e839e754f5, topicName=阿奇霉素治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLIQxicGuURvblbKDmmdLreAdrFKYA57y7viabog6mfk8dXQpQzYCf0ibcgoMnFrQ2MiaV8Iic4ocdhEfw/132, createdBy=0e3a2500177, createdName=ms1692810954239974, createdTime=Mon Jun 13 07:51:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929245, encodeId=6cf8192924567, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Mar 19 12:51:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84645, encodeId=c0d98464570, content=学习了啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Sun May 08 07:19:00 CST 2016, time=2016-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84646, encodeId=c32c84646cf, content=涨姿势了, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Sun May 08 07:19:00 CST 2016, time=2016-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050543, encodeId=71f5205054334, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jul 23 20:51:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528313, encodeId=f6f61528313dd, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sat Apr 16 05:51:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78462, encodeId=3530e8462f9, content=支原体吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Fri Apr 15 10:57:00 CST 2016, time=2016-04-15, status=1, ipAttribution=)]
    2016-05-08 卡莲

    学习了啊

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1816466, encodeId=c11018164661e, content=<a href='/topic/show?id=4e839e754f5' target=_blank style='color:#2F92EE;'>#阿奇霉素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97754, encryptionId=4e839e754f5, topicName=阿奇霉素治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLIQxicGuURvblbKDmmdLreAdrFKYA57y7viabog6mfk8dXQpQzYCf0ibcgoMnFrQ2MiaV8Iic4ocdhEfw/132, createdBy=0e3a2500177, createdName=ms1692810954239974, createdTime=Mon Jun 13 07:51:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929245, encodeId=6cf8192924567, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Mar 19 12:51:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84645, encodeId=c0d98464570, content=学习了啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Sun May 08 07:19:00 CST 2016, time=2016-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84646, encodeId=c32c84646cf, content=涨姿势了, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Sun May 08 07:19:00 CST 2016, time=2016-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050543, encodeId=71f5205054334, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jul 23 20:51:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528313, encodeId=f6f61528313dd, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sat Apr 16 05:51:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78462, encodeId=3530e8462f9, content=支原体吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Fri Apr 15 10:57:00 CST 2016, time=2016-04-15, status=1, ipAttribution=)]
    2016-05-08 卡莲

    涨姿势了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1816466, encodeId=c11018164661e, content=<a href='/topic/show?id=4e839e754f5' target=_blank style='color:#2F92EE;'>#阿奇霉素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97754, encryptionId=4e839e754f5, topicName=阿奇霉素治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLIQxicGuURvblbKDmmdLreAdrFKYA57y7viabog6mfk8dXQpQzYCf0ibcgoMnFrQ2MiaV8Iic4ocdhEfw/132, createdBy=0e3a2500177, createdName=ms1692810954239974, createdTime=Mon Jun 13 07:51:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929245, encodeId=6cf8192924567, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Mar 19 12:51:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84645, encodeId=c0d98464570, content=学习了啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Sun May 08 07:19:00 CST 2016, time=2016-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84646, encodeId=c32c84646cf, content=涨姿势了, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Sun May 08 07:19:00 CST 2016, time=2016-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050543, encodeId=71f5205054334, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jul 23 20:51:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528313, encodeId=f6f61528313dd, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sat Apr 16 05:51:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78462, encodeId=3530e8462f9, content=支原体吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Fri Apr 15 10:57:00 CST 2016, time=2016-04-15, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1816466, encodeId=c11018164661e, content=<a href='/topic/show?id=4e839e754f5' target=_blank style='color:#2F92EE;'>#阿奇霉素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97754, encryptionId=4e839e754f5, topicName=阿奇霉素治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLIQxicGuURvblbKDmmdLreAdrFKYA57y7viabog6mfk8dXQpQzYCf0ibcgoMnFrQ2MiaV8Iic4ocdhEfw/132, createdBy=0e3a2500177, createdName=ms1692810954239974, createdTime=Mon Jun 13 07:51:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929245, encodeId=6cf8192924567, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Mar 19 12:51:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84645, encodeId=c0d98464570, content=学习了啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Sun May 08 07:19:00 CST 2016, time=2016-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84646, encodeId=c32c84646cf, content=涨姿势了, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Sun May 08 07:19:00 CST 2016, time=2016-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050543, encodeId=71f5205054334, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jul 23 20:51:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528313, encodeId=f6f61528313dd, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sat Apr 16 05:51:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78462, encodeId=3530e8462f9, content=支原体吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Fri Apr 15 10:57:00 CST 2016, time=2016-04-15, status=1, ipAttribution=)]
    2016-04-16 freve
  7. [GetPortalCommentsPageByObjectIdResponse(id=1816466, encodeId=c11018164661e, content=<a href='/topic/show?id=4e839e754f5' target=_blank style='color:#2F92EE;'>#阿奇霉素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97754, encryptionId=4e839e754f5, topicName=阿奇霉素治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLIQxicGuURvblbKDmmdLreAdrFKYA57y7viabog6mfk8dXQpQzYCf0ibcgoMnFrQ2MiaV8Iic4ocdhEfw/132, createdBy=0e3a2500177, createdName=ms1692810954239974, createdTime=Mon Jun 13 07:51:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929245, encodeId=6cf8192924567, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Mar 19 12:51:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84645, encodeId=c0d98464570, content=学习了啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Sun May 08 07:19:00 CST 2016, time=2016-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84646, encodeId=c32c84646cf, content=涨姿势了, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Sun May 08 07:19:00 CST 2016, time=2016-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050543, encodeId=71f5205054334, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Jul 23 20:51:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528313, encodeId=f6f61528313dd, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sat Apr 16 05:51:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78462, encodeId=3530e8462f9, content=支原体吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Fri Apr 15 10:57:00 CST 2016, time=2016-04-15, status=1, ipAttribution=)]
    2016-04-15 1de3b290m83(暂无匿称)

    支原体吗?

    0

相关威廉亚洲官网

Obstet Gynecol:ACOG提倡使用双重抗生素治疗淋病

淋球菌对磺酰胺类、四环素、青霉素耐药,因为头孢曲松钠和阿奇霉素是一线治疗药物。在美国淋病是第二个最常见的细菌性性传播疾病,每年估计有 820,000 例新发案例。在2007年,因为淋球菌对氟喹诺酮耐药,疾控中心对淋病的治疗停止推荐氟喹诺酮,使得头孢菌素成为仅存的推荐的抗生素种类。抗生素耐药性产生后会导致治疗的失败、并发症风险增加,以及促进疾病的性传播。ACOG建议头孢曲松钠和阿奇霉素同时使用。对宫

NEJM:阿奇霉素用以消除雅司病(Yaws)

使用阿奇霉素对群体进行治疗,是WHO提出的消灭雅司病的新策略中的核心组成成分。要在全世界范围内实施该方案,那么关于该方案的有效性的使用数据是需要且必须的。Oriol Mitjà等人在巴布亚新几内亚——雅司病流行的地方进行了重复性关于活跃期雅司病的临床调查、潜伏期雅司病的血清型调查、分子分析法去明确皮肤破溃的原因、以及治疗前和阿奇霉素群体治疗6个月以及12个月后大环内酯类耐药性突变情况。最

JAMA:早期使用阿奇霉素对儿童到底是好是坏?

孩子们经常出现呼吸道感染。大多数孩子仅表现出咳嗽和鼻塞症状且较易恢复,但若疾病发展且愈加严重,则易导致孩子出现呼吸问题,需要紧急就诊。

NEJM:泌尿生殖道沙眼衣原体感染,阿奇霉素功效不及多西环素

泌尿生殖道沙眼衣原体感染仍然盛行,导致大量的生殖方面的疾病。近年来,阿奇霉素治疗衣原体感染的研究已引起人们的关注。原始出处:William M. Geisler,Apurva Uniyal,Jeannette Y. Lee,et al.Azithromycin versus Doxycycline for Urogenital Chlamydia trachomatis Infection,NEJ

NEJM:单剂量阿奇霉素群体治疗雅司病

雅司病是一种慢性传染病,由梅毒螺旋体的一种亚种导致。这是一种革兰氏阳性菌在遗传学角度与这种非性交传染的地方病雅司病密切相关。雅司病可以通过皮肤伤口的直接接触而传染。阿奇霉素用于群体治疗雅司病世界卫生组织根除雅司病的新策略的中心组成部分。这一全球性计划的实施的首要条件正是证明有效性的实验数据。为此,研究人员开展了此次试验。 研究人员对现有的雅司病进行重复性临床研究,对潜在的雅司病进行血清学

BMJ Open:新生儿使用阿奇霉素的安全性研究

研究者检索了MEDLINE、EMBASE、Pubmed等数据库中关于新生儿使用阿奇霉素的研究,以探究新生儿使用阿奇霉素和不良药物反应。该系统回顾纳入了使用过阿奇霉素的<28天的新生儿,以与阿奇霉素相关的不良事件作为主要结局,而阿奇霉素在新生儿中的使用作为继发结局。最终该系统回顾纳入了11篇相关研究,涉及473名新生儿,数据报道了371例不良事件。不良反应时事件主要包括呼吸系统 (358/1000)